Novo Nordisk (CPSE:NOVO B) Raised Its Outlook, Is The Stock Still Undervalued?
Novo Nordisk (CPSE:NOVO B) just reported third quarter 2026 earnings, giving investors fresh numbers on sales, profit and earnings per share after a mixed year for the stock. Recent trading has been choppy for Novo Nordisk, with the share price climbing 4.1% over the past week and 8.6% over the past month, but still sitting well below earlier levels after an 18.2% decline in the year to date and a 10.2% drop in 1 year total shareholder return. Stronger third quarter earnings, a higher full...
Novo Nordisk (CPSE:NOVO B) just reported third quarter 2026 earnings, giving investors fresh numbers on sales, profit and earnings per share after a mixed year for the stock. Recent trading has been choppy for Novo Nordisk, with the share price climbing 4.1% over the past week and 8.6% over the past month, but still sitting well below earlier levels after an 18.2% decline in the year to date and a 10.2% drop in 1 year total shareholder return. Stronger third quarter earnings, a higher full...
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2287372080-43ad061bfd8b449fba9246e6e0cdbe51.jpg?#)
